 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
1 News |  |
- || zanidatamab zovodotin (ZW49) / Zymeworks
Trial primary completion date, Metastases: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers (clinicaltrials.gov) - Dec 15, 2023
P1, N=174, Active, not recruiting, Sponsor: Zymeworks Inc.
Trial primary completion date: Aug 2023 --> Aug 2025
- zanidatamab (ZW25) / Jazz, zanidatamab zovodotin (ZW49) / Zymeworks
Phase 1 Study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in Patients with Human Epidermal Growth Factor2 (HER2)-positive Solid Cancers. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_449;
- || zanidatamab zovodotin (ZW49) / Zymeworks
Enrollment closed, Metastases: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers (clinicaltrials.gov) - May 11, 2023
P1, N=174, Active, not recruiting, Sponsor: Zymeworks Inc.
Trial primary completion date: Aug 2023 --> Aug 2025 Recruiting --> Active, not recruiting
- zanidatamab (ZW25) / Jazz, zanidatamab zovodotin (ZW49) / Zymeworks
Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer (Section 13; Poster Board #1) - Mar 14, 2023 - Abstract #AACR2023AACR_4860;
P1
Anti-tumor activity was observed in 5/7 (71%) PDX models of gastric cancer after a single i.v. dose of 6 mg/kg, including in models with moderate and weak HER2 expression. The strong anti-tumor activity of ZW-49 in vivo, together with its ability to induce ICD and potential adaptive immune responses, support ZW49 as a promising ADC for the treatment of HER2-expressing cancers warranting further investigation, including potential combination with checkpoint inhibitors.
- || Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, zanidatamab zovodotin (ZW49) / Zymeworks
Clinical: Hope $ZYME plan to layer a PD-1 on top of ZW49 in any post-ENHERTU patient segment (?) Even then, that dose-limiting ocular tox! (Twitter) - Nov 16, 2022
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, zanidatamab zovodotin (ZW49) / Zymeworks
Ken Galbraith ( $ZYME CEO as of 10mths ago) highlighting ZW49. Says he's convinced it has a place behind Kadcyla & Enhertu, and lies outside the $JAZZ deal #Jefferies22 (Twitter) - Nov 16, 2022
- ||||| zanidatamab (ZW25) / Zymeworks, zanidatamab zovodotin (ZW49) / Zymeworks
Clinical, Monotherapy: According to data from a first-in-human phase 1 trial, zanidatamab zovodotin produced encouraging responses & had manageable toxicity when used as a monotherapy in heavily pretreated patients with HER2+ solid cancers. @jhaveri_komal @MSKCancerCenter https://t.co/isdCaGa4Sp (Twitter) - Oct 9, 2022
- |||| zanidatamab (ZW25) / Zymeworks, zanidatamab zovodotin (ZW49) / Zymeworks
Clinical, Monotherapy: Zanidatamab zovodotin was found to produce encouraging responses and to have a manageable toxicity profile when used as a monotherapy in heavily pretreated patients with HER2+ solid cancers. @jhaveri_komal @MSKCancerCenter https://t.co/KD1AmlayQx (Twitter) - Oct 7, 2022
- |||| zanidatamab (ZW25) / Zymeworks, zanidatamab zovodotin (ZW49) / Zymeworks
Zymeworks ($ZYME) ZW49 zanidatamab anti-biparatopic Her2+zovodotin auristatin against HER2+ breast and gastric cancers https://t.co/2x8eP11zTN #ESMO22 (Twitter) - Sep 20, 2022
- zanidatamab (ZW25) / Zymeworks, zanidatamab zovodotin (ZW49) / Zymeworks
Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers (7.3.T - Toulouse Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1804;
P1
Conclusions ZW49 has a manageable safety profile with encouraging single-agent antitumor activity in heavily pretreated pts with HER2+ cancers. Enrollment continues at 1.75 mg/kg QW in DE and 1.5 mg/kg QW in DX.
- || zanidatamab zovodotin (ZW49) / Zymeworks
Trial completion date, Trial primary completion date, Metastases: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers (clinicaltrials.gov) - Jun 30, 2021
P1, N=174, Recruiting, Sponsor: Zymeworks Inc.
Enrollment continues at 1.75 mg/kg QW in DE and 1.5 mg/kg QW in DX. Trial completion date: Apr 2023 --> Aug 2025 | Trial primary completion date: May 2021 --> Aug 2023
- | ZW49 / Zymeworks
Journal: First report of postharvest fruit rot on passion fruit (Passiflora edulis) caused by Lasiodiplodia theobromae in Mainland China. (Pubmed Central) - Nov 5, 2020
Two isolates (ZW 49-1 and ZW 50-1) were randomly selected to further study...The occurrence of fruit rot on passion fruit caused by L. theobromae was reported in Taiwan, China recently (Huang et al., 2019). To our knowledge, this is the first report of L. theobromae causing postharvest fruit rot on passion fruit in the Chinese mainland.
- || ZW49 / Zymeworks
Clinical: I dunno - reading the limited communications on ZW49 thus far, I'd say they likely started too low in dosing but are now reaching more promising efficacy as they continue to seek the MTD (Twitter) - Sep 14, 2020
- ZW49 / Zymeworks
[VIRTUAL] ZW49: Combining Zymeworks’ Platforms to Expand the Therapeutic Window of ADCs in HER2-Positive Cancer () - Aug 31, 2020 - Abstract #PEGS2020PEGS_195;
ZW49 is a bispecific antibody-drug conjugate that combines the ZymeLink™ linker-payload with the unique mechanisms of action of a biparatopic, anti-HER2 Azymetric antibody. ZW49 has the potential to address the unmet medical need across a range of HER2-expressing cancers.
- | ZW49 / Zymeworks
Whats value are you attributing to zw49? (Twitter) - May 14, 2020
- || zanidatamab zovodotin (ZW49) / Zymeworks
Enrollment change, Metastases: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers (clinicaltrials.gov) - Dec 23, 2019
P1, N=150, Recruiting, Sponsor: Zymeworks Inc.
ZW49 has the potential to address the unmet medical need across a range of HER2-expressing cancers. N=69 --> 150
- || ZW49 / Zymeworks
Preclinical: don't forget ZW49, it cures mice much better haha (Twitter) - Dec 11, 2019
- || ZW49 / Zymeworks
though in January at JPM only sime qualitative data for ZW49. mire relevant data at ASCO in May! $ZYME (Twitter) - Dec 11, 2019
- | ZW49 / Zymeworks
exactly. first preliminiary $ZYME ZW49 data beginning of 2020 at JPM. (Twitter) - Oct 21, 2019
- || ZW25 / Zymeworks, ZW49 / Zymeworks
Preclinical: The ADC version of ZW25 - ZW49 - is entering the clinic now. Preclinical data were impressive (large therapeutic window & tumor regression) with the usual grain of salt. (Twitter) - Jun 4, 2019
- | ZW25 / Zymeworks, ZW49 / Zymeworks
2 missing from the list are $ZYME bispecific anti-HER2 mAb ZW25 in ph2 and bispecific anti-HER2 mAb ADC ZW49 in ph1 https://t.co/ozdDsGn9Wc https://t.co/kUTt4EorcC (Twitter) - May 8, 2019
- ||| zanidatamab zovodotin (ZW49) / Zymeworks
New P1 trial, Metastases: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers (clinicaltrials.gov) - Jan 29, 2019
P1, N=69, Recruiting, Sponsor: Zymeworks Inc.